Lung Cancer

Case Report, Lung Cancer

Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer

Matthew S. Mattila, PharmD, BCPS, BCOP; Joel H. Lundberg, MD, FACP

FDA Updates, Lung Cancer

Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC

FDA Updates, Lung Cancer

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

FDA Updates, Lung Cancer

Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations

Lung Cancer

NSCLC Year in Review Introduction

Lung Cancer

ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC

Lung Cancer

Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation

Lung Cancer

Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations

Lung Cancer

Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC

Lung Cancer

Inhibition of VEGFR and EGFR with Apatinib + Gefitinib as First-Line Therapy Increased Progression-Free Survival

1
2
3
4

Page 1 of 9
Results 1 - 10 of 82

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.